Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $112.65 (market cap $16.78B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: iShares 3 7 Year Treasury Bond ETF is far larger — about 17.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 45 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IEI | MRVI | |
|---|---|---|
Market Cap | $16.78B | $972.90M |
Volume | 2,469,699 | 4,325,710 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $9.00 |
52-Week Low | $113.17 | $2.83 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.57 with minimal daily movement (+0.08%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $114 and support at $113. Recent dividend payments of $0.37-$0.38 per share demonstrate shareholder returns, but key valuation metrics (P/E, P/S, P/B) are unavailable for fundamental assessment.
The outlook remains cautious due to the bearish technical setup and lack of fundamental visibility. Bond market volatility highlighted in recent news (Bloomberg, Reuters September 2026) could impact financial sector sentiment. Investment appeal hinges on forthcoming financial disclosures to validate valuation, while current technical resistance near $114 limits near-term upside potential.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
